Medical Condition News

RSS

NDA resubmitted for DURECT's ORADUR technology based REMOXY

DURECT Corporation today reported that King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. have announced that King has resubmitted a New Drug Application (NDA) for REMOXY® to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter received by Pain Therapeutics in December 2008. This is a Class 2 resubmission with a six month review cycle.

28 Dec 2010

Researchers receive $6.78 million NIH grant for community-based study on heart disease

Researchers at the Methodist DeBakey Heart & Vascular Center in Houston were recently awarded a $6.78 million grant from the National Institutes of Health to extend a 23-year-old large-scale, community-based study of heart disease.

27 Dec 2010

Vitamin D levels of newborns appear to predict their risk of respiratory infections

The vitamin D levels of newborn babies appear to predict their risk of respiratory infections during infancy and the occurrence of wheezing during early childhood, but not the risk of developing asthma. Results of a study in the January 2011 issue of Pediatrics support the theory that widespread vitamin D deficiency contributes to risk of infections.

27 Dec 2010

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

During ICMS Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.

27 Dec 2010

Great River Medical Center's Board of Directors approve construction of new long-term-care center

Great River Medical Center's Board of Directors has approved construction of a new long-term-care center on the hospital's West Burlington, Iowa campus. It will replace the existing Klein Center at 2910 Madison Ave., Burlington, Iowa.

27 Dec 2010

Near-complete data sets from fruit fly and roundworm genomes

An Ontario researcher has played a key role in the development of a new resource that will help genomics researchers around the world find new ways to prevent and treat cancer.

24 Dec 2010

New study shows striking changes, variations by region in admission rates for substance abuse treatment

Although the overall rate of admissions to substance abuse treatment in the U.S. remained stable between 1998 and 2008, at about 770 admissions for every 100,000 persons in the population, a new study shows striking changes and variations in admission rates by region. For example, the rate of admissions for alcohol as the primary drug has declined by 15 percent nationally. However admission rates for alcohol in West North Central states (Ark., Iowa, Kan., Minn., Mo., N.D., Neb. and S.D.) remained the same.

24 Dec 2010

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

University of Arizona researchers may have found a way to deliver chemotherapeutic drugs to cancer tissues in controlled doses without harming healthy body cells.

24 Dec 2010

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

Two studies appearing in the current issue of Cell Transplantation 19(10) discuss stem cells derived from adipose (fat) cells and their potential use in plastic surgery and tissue reconstruction. The studies are now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ .

24 Dec 2010

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.

24 Dec 2010

Good Clostridia prevents development of allergies and inflammatory bowel disease

Scientists at the University of Tokyo have discovered that specific gut-dwelling bacteria control key immune cells that combat allergies and autoimmune diseases. The paper describing these findings was published in today's issue of the journal Science, and technology originating from the work is being advanced by start-up Vedanta Biosciences.

24 Dec 2010

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)-an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured.

24 Dec 2010

Molecular-level insights into how physical activity influences the heart

Everyone knows that exercise comes with metabolic and cardiovascular benefits, but scientists understand surprisingly little about how physical activity influences the heart itself. Now, a new study in the December 23rd issue of Cell, a Cell Press publication, offers some of the first molecular-level insights.

24 Dec 2010

Scientists tweak gene to mimick heart-strengthening effects of endurance training in sedentary mice

By tweaking a single gene, scientists have mimicked in sedentary mice the heart-strengthening effects of two weeks of endurance training, according to a report from Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC).

24 Dec 2010

Sequestering GSK3 enzyme leads to stabilization of proteins in cells

The cell signaling pathway known as Wnt, commonly activated in cancers, causes internal membranes within a healthy cell to imprison an enzyme that is vital in degrading proteins, preventing the enzyme from doing its job and affecting the stability of many proteins within the cell, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.

24 Dec 2010

Silencing of specific genes of germinal cell lines reduces brain tumors

Scientists at IRB Barcelona have discovered that some brain tumours in larvae of the fruit fly Drosophila melanogaster use the genetic programme of germline cells to grow. The removal of some of these genes leads to healthy brains. This finding demonstrates that these genes are crucial for tumour development. The study, headed by ICREA researcher Cayetano Gonz-lez, is published today in the prestigious journal Science.

24 Dec 2010

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Teva Pharmaceutical Industries Ltd. announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for a lower-volume (0.5mL) injection of glatiramer acetate. Copaxone® containing 20mg of glatiramer acetate in 1ml is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS).

24 Dec 2010

Alimera receives FDA CRL for ILUVIEN NDA

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

24 Dec 2010

Researchers study relationship between MITF, ATF2 in melanoma development

Melanoma is one of the least common types of skin cancer, but it is also the most deadly. Melanocytes (pigment-producing skin cells) lose the genetic regulatory mechanisms that normally limit their number, allowing them to divide and proliferate out of control. One such regulator, called MITF, controls an array of genes that influence melanocyte development, function and survival.

24 Dec 2010

Medical Condition News

NDA resubmitted for DURECT's ORADUR technology based REMOXY

Researchers receive $6.78 million NIH grant for community-based study on heart disease

Vitamin D levels of newborns appear to predict their risk of respiratory infections

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

Great River Medical Center's Board of Directors approve construction of new long-term-care center

Near-complete data sets from fruit fly and roundworm genomes

New study shows striking changes, variations by region in admission rates for substance abuse treatment

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

AMPK activates autophagy by activating ATG1 enzyme

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Good Clostridia prevents development of allergies and inflammatory bowel disease

Quercetin and resveratrol may play an important role in inflammation and insulin resistance

Molecular-level insights into how physical activity influences the heart

Scientists tweak gene to mimick heart-strengthening effects of endurance training in sedentary mice

Sequestering GSK3 enzyme leads to stabilization of proteins in cells

Silencing of specific genes of germinal cell lines reduces brain tumors

Teva receives FDA complete response letter for glatiramer acetate 0.5mL injection sNDA

Alimera receives FDA CRL for ILUVIEN NDA

Researchers study relationship between MITF, ATF2 in melanoma development

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News